(March 25, 2025, Shanghai, China) On March 25, 2025, Shanghai Fosun Pharmaceutical (Group) Co., Ltd. (“Fosun Pharma”or “the Group”; Stock Code: 600196.SH, 02196.HK),a leading global pharmaceutical and healthcare company driven by innovation, announced its annual results for the year ended 31 December 2024 (“the Reporting Period”).

Shanghai, China, March 24, 2025 – Henlius (2696.HK) announced its 2024 annual results. During the reporting period, Henlius’ total revenue reached approximately RMB5.7244 billion, representing an increase of 6.1% YoY. The net profit reached RMB820.5 million, a 50.3% YoY growth, with a net profit margin of 14.3%, up by 41.6% YoY. This marks Henlius' second consecutive year of full-year profitability following its first profitable year in 2023. The increasing commercial sales of core products have been a key driver of profitability, with total product sales revenue reaching approximately RMB4.9335 billion, an increase of 8.3% YoY. Additionally, the company’s annual R&D expenditure reached RMB1.8405 billion, representing an increase of 28.4% YoY.

Hong Kong, March 19, 2025 -- Sisram Medical Ltd (the “Company” or “Sisram”, 1696.HK; together with its subsidiaries collectively referred to as the “Group”), a global consumer wellness group, featuring a distinguished synergistic ecosystem of business building blocks and consumer-focused approaches including Energy-Based Devices (EBD), Injectables, alongside other complementary offerings, announced its audited consolidated annual results for the year ended December 31, 2024 (the “Reporting Period”).

Shanghai, China, March 19, 2025 - Shanghai Henlius Biotech, Inc. (2696.HK) announced that the US Food and Drug Administration (FDA) has granted Orphan Drug Designation (ODD) for HLX22, the company's innovative anti-HER2 monoclonal antibody (mAb) for the treatment of gastric cancer.

March 13, 2025 – Fosun Pharma announced that its subsidiary S-INFINITY Co., Ltd. (“S-INFINITY”) recently received approval from the National Medical Products Administration (NMPA) to conduct clinical trials for XH-S003 Capsule (registration category: chemical drug Class 1; hereinafter referred to as “XH-S003”) for the treatment of Paroxysmal Nocturnal Hemoglobinuria (PNH). S-INFINITY plans to initiate Phase 2 clinical trials in Mainland China (excluding Hong Kong, Macao, and Taiwan regions) once conditions are met.

March 10, 2025 – Recently, Fosun Pharma announced that the marketing authorization application for its independently developed new drug, foritinib Succinate Capsules (project code: SAF-189, foritinib, hereinafter referred to as "New Drug"), has been accepted by the National Medical Products Administration (NMPA). The New Drug is primarily indicated for the treatment of non-small cell lung cancer (ALK+) and non-small cell lung cancer (ROS1+), etc. The indication under this application is for the treatment of patients with anaplastic lymphoma kinase (ALK)-positive locally advanced or metastatic non-small cell lung cancer (NSCLC).

Recently, Henlius successfully hosted an in-person clinical investigator meeting for the HLX22-GC-301 study in Tokyo, Japan. The meeting focused on the international phase 3 clinical trial (HLX22-GC-301) of HLX22, our innovative anti-HER2 monoclonal antibody (mAb)

Recently, the updated 3-year follow-up results of the international multicenter Phase 3 clinical trial HLX02-BC01(NCT03084237 and EudraCT: 2016-000206-10) of HANQUYOU (trastuzumab, trade name: HERCESSI™ in the U.S., Zercepac^® in Europe), led by Academician Binghe Xu, director of the National New Drug (Antitumor) Clinical Research Center of Cancer Hospital Chinese Academy of Medical Sciences, were published in the professional breast cancer journal The Breast. The follow-up analysis results demonstrated that HANQUYOU exhibited comparable long-term efficacy, safety, and immunogenicity to the reference trastuzumab in patients with previously untreated HER2-positive metastatic breast cancer, further validating their clinical equivalence.

(26 February, 2025, Shanghai, China) — Shanghai Fosun Pharmaceutical (Group) Co., Ltd. (Fosun Pharma; stock code: 600196.SH, 02196.HK) announced that its holding subsidiary, Shanghai Fosun Pharmaceutical Industrial Development Co., Ltd. (“Fosun Pharma Industrial”), has received approval from the National Medical Products Administration (“NMPA”) for the New Drug Application (“NDA”) for Tenapanor Hydrochloride Tablets (Chinese trade name: Wan Ti Le, the “New Drug”), an innovative phosphate absorption inhibitor with a novel mechanism, with the indication being for the control of serum phosphorus levels in dialysis patients with chronic kidney disease (CKD) who have an inadequate response or are intolerant to phosphorus binders.